Jounce Therapeutics Inc. (JNCE)

[now invest]

Wow.... up 11% as of now!! 5.48!!

[now invest]

LOL!!! Glad I bought more yesterday....!! 2.5.. LOL!!!!

[123tom]

JNCE has made a strong rally BUT

I think its getting overextended here. could get hammered down soon.
If its making a double off the 2.75 low...
needs a little cooling off here. too fast the bubble is getting pumped here. retrace target zone 4.00-3.60
just my opinion.

[justthefactsmam]

https://finance.yahoo.com/news/value-etfs-stocks-offering-real-130001964.html

[now invest]

One thing is that RJ reiterated a 10 dollar target.... and gave updated estimates on financials..... added a few more yesterday.....??

[123tom]

What caused JNCE to soar today???

[123tom]

Big move today.

would it make a big pullback from this soon. like its done many times.

JNCE chart

This is the track pattern that seems about right,based on the math

[now invest]

Well now well into the 4s!!! RJ has $10 target!!

[123tom]

I'm starting to watch Jounce.

it has been making a rally from the double bottom (2.75 area)
peaks at 3.98 so far, and looks to be pulling back now. There is newsy conference next week. and some time this week for this pullback to hit a shoulder zone . It looks like this rally from the 2.75 Low,thru October is a run up into the conference... ? so I'm watching any pullback now as a possible first entry spot. maybe if it falls to 3.50-3.40-3.30 area,a small entry to start.

Did investors and traders think JNCE would fall down like it did ,to 2.75?

What should one call the top zone? 12 area? 13? surely not 20 and 30 dollars like before.
Its a big collapse to bottom at 2.75

JNCE chart

[TFMG]

JNCE - Huge Buyers Hit Market At Different Trading Price

Jounce Therapeutics Inc (NASDAQ: JNCE ) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG ), the latter of which has agreed to be acquired by Bristol-Myers Squibb Co (NYSE: BMY ). (Source: https://finance.yahoo.com/news/know-joun...)

Jounce Therapeutics , Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

SHORT INTEREST
456.94K 06/28/19

P/E Ratio (with extraordinary items)
-5.04

Analyst Target Price $12.50

Recommendation: HOLD

[now invest]

NICE NEWS!!!! UP OVER $1.00 AFTER HOURS!!

[wiltonio]

Partner Fund Management, L.P. has filed a new 13G, reporting 5.4% ownership in $JNCE - https://fintel.io/i/partner-fund-management and https://fintel.io/i/partner-fund-management

[stocktrademan]

JNCE bullish 24.61

bull flag









normal chart




log chart